This meeting was organized by The Transplantation Society with the assistance of an
unconditional education grant from CSL Behring. CSL Behring had no involvement in the …

Late antibody‐mediated rejection (ABMR) is a cardinal cause of kidney allograft failure,
manifesting as a continuous and, in contrast with early rejection, often clinically silent …

Extending the functional integrity of renal allografts is the primary goal of transplant
medicine. The development of donor-specific antibodies (DSAs) posttransplantation leads to …

There are no approved treatments for chronic antibody mediated rejection (ABMR). We
conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical …

We report results of a phase 2, randomized, multicenter, open-label, two-arm study
evaluating the safety and efficacy of eculizumab in preventing acute antibody-mediated …

Background. Antibody-mediated rejection (AMR) is a leading cause of morbidity and
mortality after kidney transplantation. Early diagnosis and treatment of subclinical AMR …

Introduction Chronic active antibody‐mediated rejection (cAMR) is a major determinant of
late allograft failure. Rituximab/immunoglobulins (IVIg)+ plasma exchange (PLEX) showed …

Background Chronic active antibody-mediated rejection (AMR) is a major cause of graft loss
with no approved drugs for its treatment. Currently, off-label regimens are used, reflecting …

Background: Chronic antibody injury is a serious threat to allograft outcomes and is
therefore the center of active research. In the continuum of allograft rejection, the …

Rituximab is a B-lymphocyte depleting agent that is used to treat hematological
malignancies and autoimmune diseases. Recently, it has gained interest as an …